Page last updated: 2024-08-22

buthionine sulfoximine and Inclusion Body Myopathy, Sporadic

buthionine sulfoximine has been researched along with Inclusion Body Myopathy, Sporadic in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Abe, T; Akiyama, Y; Aoki, M; Hagiwara, Y; Hayashi, H; Hayashi, KI; Ichijo, M; Itoi, E; Izumi, R; Kanzaki, M; Kikuchi, K; Kodama, EN; Koide, M; Kure, S; Matsuhashi, T; Mishima, E; Ogata, Y; Oikawa, Y; Suzuki, C; Suzuki, N; Suzuki, T; Toyohara, T; Watanabe, S1

Other Studies

1 other study(ies) available for buthionine sulfoximine and Inclusion Body Myopathy, Sporadic

ArticleYear
Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5.
    PloS one, 2020, Volume: 15, Issue:12

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Buthionine Sulfoximine; Cell Survival; Cells, Cultured; DNA, Mitochondrial; Drug Evaluation, Preclinical; Dynamins; Female; Fibroblast Growth Factors; Fibroblasts; Growth Differentiation Factor 15; GTP Phosphohydrolases; Humans; Indoleacetic Acids; Male; Middle Aged; Mitochondria, Muscle; Myoblasts; Myositis, Inclusion Body; Oxygen Consumption; Phenylbutyrates; Reactive Oxygen Species; Retrospective Studies

2020